Expert analysis to help choose the right peptide therapy
When researchers ran publicly available third-party tests on fourteen gray-market peptides, BPC-157 among them, more than forty percent of over six thousand samples failed to meet basic purity and dose standards, and of the smaller batch screened for bacterial endotoxins, fifteen percent carried measurable contamination, the kind that at high enough doses brings on fever, chills, and septic shock
Every batch is independently tested by Janoshik Labs for purity and contaminants
It mobilizes fatty acids from adipose tissue, particularly visceral fat, and shifts metabolism toward fat oxidation
Safety, Side Effects, and Legal Status No human safety trial for BPC-157 by any route has been published
Stephens, PhD